News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Imfinzi Approved in EU as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer
Friday, July 04, 2025AstraZenecas Imfinzi durvalumab has been approved by the European Commission for use in adult patients with resectable muscleinvasive bladder cancer MIBC The treatment involves a combination of Imfinzi with gemcitabine and cisplatin as neoadjuvant th...
Instil Bio Receives FDA Clearance to Begin Phase 1 Trial of AXN-2510 for Relapsed or Refractory Solid Tumours
Thursday, July 03, 2025Instil Bio Inc a clinicalstage biopharmaceutical company listed on NASDAQ TIL has announced that the US Food and Drug Administration FDA has cleared its Investigational New Drug IND application for AXN This is a PDLxVEGF bispecific antibody developed...
Jazz Pharmaceuticals Gains Conditional EU Approval for Ziihera® to Treat Advanced HER2-Positive Biliary Tract Cancer
Wednesday, July 02, 2025Jazz Pharmaceuticals plc has received conditional marketing authorisation from the European Commission EC for Ziihera zanidatamab as a treatment for adults with unresectable locally advanced or metastatic HERpositive biliary tract cancer BTC who have...
Vertex Receives European Commission Approval for ALYFTREK®, a New Once-Daily Treatment for Cystic Fibrosis
Wednesday, July 02, 2025Vertex Pharmaceuticals has announced that the European Commission has granted approval for ALYFTREK a oncedaily cystic fibrosis transmembrane conductance regulator CFTR modulator
Takeda Gains U.S. FDA Approval for GAMMAGARD LIQUID ERC, a Ready-to-Use Low-IgA Immunoglobulin Therapy
Tuesday, July 01, 2025Takeda has received approval from the US Food and Drug Administration FDA for GAMMAGARD LIQUID ERC an immune globulin infusion human with low immunoglobulin A IgA content The approved formulation
Iksuda Therapeutics Secures FDA IND Clearance for IKS014 Targeting HER2-Positive Solid Tumours
Tuesday, July 01, 2025Iksuda Therapeutics has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for IKS an antibodydrug conjugate ADC designed to target HERpositive
FDA Approves Gamifant® as First Treatment for Macrophage Activation Syndrome in Still’s DiseaseFDA Approves Gamifant® as First Treatment for Macrophage Activation Syndrome in Still’s Disease
Monday, June 30, 2025Sobi has received approval from the US Food and Drug Administration FDA for its medicine Gamifant emapalumablzsg to treat both adults and children including newborns with hemophagocytic lymphohistiocytosis
ProFound Therapeutics Enters Four-Year Collaboration with Novartis to Develop Cardiovascular Treatments
Friday, June 27, 2025ProFound Therapeutics has entered a strategic fouryear collaboration with Novartis to discover and develop new treatments for cardiovascular disease The partnership will make use of ProFounds proprietary ProFoundry Platform
Invetech and AiCella Form Strategic Partnership to Drive Innovation in Cell Therapy Development
Friday, June 27, 2025Invetech a global provider of advanced manufacturing and product development solutions has announced a strategic partnership with AiCella a company leveraging artificial intelligence to enhance the development of cell therapy manufacturing processes...
Gilead Sciences and Kymera Therapeutics Sign Exclusive Agreement to Develop New CDK2-Targeting Cancer Treatment
Thursday, June 26, 2025Gilead Sciences and Kymera Therapeutics have entered into an exclusive option and licence agreement aimed at advancing the development and commercialisation of a novel oral molecular glue degrader MGD programme
